The contributing effect of such changes on sleep problems in patients with type-2 diabetes may also be interesting to explore in future studies, as SGLT-2 inhibitors have yielded promising results for the treatment of OSA (Tanriover et al., 2023), and we cannot rule out that effect. Here, SLC5A2 is linked to obstructive sleep apnea syndrome.